IntelGenx Provides Update on Phase 2a Montelukast VersaFilm Clinical Trial
IntelGenx (TSXV:IGX,OTCQX:IGXT) a leading oral drug delivery company, provided an update on its Phase 2a study of Montelukast VersaFilm in patients with mild to moderate Alzheimer’s Disease (AD). As quoted in the press release: To date, seven study sites across Canada have randomized eight subjects, many of which commenced dosing in late-2018. IntelGenx sponsored study …
IntelGenx (TSXV:IGX,OTCQX:IGXT) a leading oral drug delivery company, provided an update on its Phase 2a study of Montelukast VersaFilm in patients with mild to moderate Alzheimer’s Disease (AD).
As quoted in the press release:
To date, seven study sites across Canada have randomized eight subjects, many of which commenced dosing in late-2018. IntelGenx sponsored study sites are actively screening for new patients and IntelGenx expects enrollment to accelerate following the holiday season hiatus. In addition to opening its planned eighth trial site, IntelGenx is preparing to open an additional site in Montreal, bringing the total number of sites to nine.
“We are looking forward to commencing patient recruitment at our eighth site in the coming weeks, as well as opening an additional site in Montreal by the end of first quarter 2019,” said Dr. Horst G. Zerbe, President and CEO of IntelGenx. “Although in its early stages, this is an exciting trial for IntelGenx as we work with our study sites to achieve a shared goal of finding a treatment that benefits patients living with this most unfortunate and debilitating disease.”
“Unlike traditional dosage forms, our Montelukast VersaFilm™ is engineered to deliver Montelukast with an improved bioavailability, which may be more efficacious than known Montelukast dosage forms in crossing the blood-brain barrier,” contends Dr. Zerbe. “As a result, our VersaFilm™ technology has the potential to be broadly applicable to a wide variety of other pharmaceutical treatment options.”
MARKETS
COMMODITIES
Commodities | |||
---|---|---|---|
Gold | 1796.89 | -9.97 | |
Silver | 19.68 | -0.58 | |
Copper | 3.59 | -0.12 | |
Palladium | 1936.50 | +14.50 | |
Platinum | 875.00 | -22.00 | |
Oil | 107.97 | +2.21 | |
Heating Oil | 4.00 | +0.17 | |
Natural Gas | 5.82 | +0.40 |
DOWNLOAD FREE REPORTS
BROWSE COMPANIES BY SECTOR
- Agriculture Investing
- Phosphate Investing
- Potash Investing
- Base Metals Investing
- Copper Investing
- Iron Investing
- Lead Investing
- Nickel Investing
- Zinc Investing
- Battery Metals Investing
- Cobalt Investing
- Graphite Investing
- Lithium Investing
- Manganese Investing
- Vanadium Investing
- Critical Metals Investing
- Magnesium Investing
- Rare Earth Investing
- Scandium Investing
- Tantalum Investing
- Tellurium Investing
- Tungsten Investing
- Energy Investing
- Oil and Gas Investing
- Uranium Investing
- Gem Investing
- Diamond Investing
- Industrial Metals Investing
- Aluminum Investing
- Chromium Investing
- Coal Investing
- Molybdenum Investing
- Tin Investing
- Precious Metals Investing
- Gold Investing
- Palladium Investing
- Platinum Investing
- Silver Investing
- 3D Printing Investing
- Bitcoin Investing
- Blockchain Investing
- Cleantech Investing
- Cloud Investing
- Cryptocurrencies
- Data Investing
- Emerging Tech Investing
- Artificial Intelligence Investing
- Mobile Investing
- Robotics Investing
- Fintech Investing
- Gaming Investing
- Esports Investing
- Nanoscience Investing
- Graphene Investing
- Nanotech Investing
- Security Investing
Featured stocks
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.